creactiv
protein
crp
myxoviru
resist
protein
mxa
associ
bacteri
viral
infect
respect
conduct
prospect
multicent
crosssect
studi
adult
children
febril
upper
respiratori
tract
infect
uri
evalu
diagnost
accuraci
rapid
crpmxa
immunoassay
identifi
clinic
signific
bacteri
infect
host
respons
acut
pathogen
viral
infect
refer
standard
classifi
uri
etiolog
algorithm
includ
throat
bacteri
cultur
upper
respiratori
pcr
viral
atyp
pathogen
procalcitonin
white
blood
cell
count
bandemia
algorithm
also
allow
physician
overrid
among
patient
classifi
bacteri
viral
neg
refer
standard
bacteri
detect
agreement
febridx
refer
standard
febridx
sensit
ci
specif
posit
predict
valu
ppv
neg
predict
valu
npv
viral
detect
agreement
sensit
specif
ppv
npv
febridx
may
help
identifi
clinic
signific
immun
respons
associ
bacteri
viral
uri
like
requir
clinic
manag
therapeut
intervent
potenti
assist
antibiot
stewardship
acut
respiratori
infect
ari
common
reason
oral
antibiot
prescript
unit
state
recent
data
suggest
approxim
antibiot
use
outpati
set
inappropri
larg
driven
misus
antibiot
viral
upper
respiratori
tract
uri
infect
overus
antibiot
link
sever
neg
outcom
includ
develop
antibiot
resist
antibioticassoci
infect
increas
cost
drug
toxic
antibiot
stewardship
program
focu
guid
clinician
use
antibiot
uri
adequ
evid
bacteri
infect
exist
howev
rapid
diagnost
test
assist
clinician
identif
bacteri
respiratori
infect
lack
hamper
antibiot
stewardship
effort
febridx
rp
diagnost
sarasota
fl
usa
new
pointofcar
diagnost
test
design
rapidli
identifi
host
immun
respons
associ
bacteri
viral
infect
goal
provid
clinician
realtim
accur
inform
assist
antibiot
prescrib
decis
uri
febridx
provid
qualit
result
elev
serum
level
creactiv
protein
crp
acut
phase
reactant
associ
bacteri
infect
myxoviru
resist
protein
mxa
deriv
associ
viral
infect
purpos
studi
evalu
diagnost
accuraci
febridx
test
identifi
immun
respons
associ
bacteri
viral
uri
patient
acut
fever
uri
symptom
like
requir
clinic
manag
therapeut
intervent
present
less
clinic
signific
microbiolog
unconfirm
respiratori
ill
muri
prospect
cross
section
observ
studi
use
conveni
sampl
febril
patient
clinic
sign
symptom
uri
children
adult
enrol
januari
novemb
clinic
site
us
includ
academ
emerg
depart
commun
urgent
care
center
ambulatori
clinic
research
site
major
inclus
criteria
includ
age
year
new
fever
f
within
past
day
new
onset
cough
sore
throat
within
past
day
major
exclus
criteria
includ
recent
histori
trauma
surgeri
use
antibiot
antivir
agent
interferon
therapi
immunosuppress
therapi
live
viral
immun
within
past
day
full
elig
list
supplement
tabl
studi
approv
govern
institut
review
board
enrol
center
written
inform
consent
obtain
particip
legal
author
repres
appropri
patient
underw
test
febridx
rapid
qualit
singleus
dispos
whole
blood
immunoassay
turnaround
time
min
febridx
requir
mcl
whole
blood
obtain
capillari
finger
stick
provid
qualit
result
elev
level
crp
mgl
mxa
ngml
current
univers
mxa
elisa
standard
mxa
elisa
use
determin
medic
decis
point
febridx
mxa
result
line
standard
materi
biovend
mxa
elisa
biovend
brno
czech
republ
use
truncat
recombin
mxa
construct
less
prone
aggreg
assay
condit
also
contain
high
salt
content
ensur
monomer
mxa
taken
togeth
factor
tend
dramat
enhanc
accuraci
importantli
reproduc
assay
explain
febridx
mxa
medic
decis
point
near
ngml
versu
ngml
seen
mxa
elisa
test
febridx
result
indic
elev
crp
without
associ
elev
mxa
interpret
bacteri
infect
febridx
result
indic
elev
mxa
regardless
crp
level
interpret
viral
infect
valid
test
show
elev
crp
mxa
interpret
neg
studi
personnel
site
obtain
whole
blood
sampl
finger
stick
perform
febridx
test
accord
manufactur
instruct
interpret
result
bacteri
viral
neg
personnel
perform
febridx
test
blind
refer
test
outlin
febridx
result
use
clinic
care
use
referencetest
algorithm
combin
physician
panel
overread
refer
standard
identifi
type
infect
present
figur
outcom
interest
acut
bacteri
infect
host
respons
acut
pathogen
viral
infect
procalcitonin
pct
white
blood
cell
wbc
count
use
refer
standard
identifi
host
respons
virus
typic
pathogen
detect
upper
respiratori
tract
list
classifi
acut
viral
infect
meanwhil
virus
commonli
colon
respiratori
tract
without
caus
symptom
rhinoviru
produc
latent
infect
period
dna
shed
herp
simplex
viru
hsv
consid
acut
pathogen
infect
studi
use
referencetest
algorithm
combin
physician
panel
overread
refer
standard
identifi
type
infect
present
figur
outcom
interest
acut
bacteri
infect
host
respons
acut
pathogen
viral
infect
procalcitonin
pct
white
blood
cell
wbc
count
use
refer
standard
identifi
host
respons
virus
typic
pathogen
detect
upper
respiratori
tract
list
classifi
acut
viral
infect
meanwhil
virus
commonli
colon
respiratori
tract
without
caus
symptom
rhinoviru
produc
latent
infect
period
dna
shed
herp
simplex
viru
hsv
consid
acut
pathogen
infect
studi
refer
test
algorithm
illustr
figur
patient
underw
follow
diagnost
test
throat
swab
bacteri
cultur
multiplex
polymeras
chain
reaction
pcr
combin
nasopharyng
oropharyng
npop
sampl
use
filmarray
respiratori
panel
biomerieux
inc
marcyletoil
franc
realtim
revers
transcriptas
pcr
npop
sampl
epsteinbarr
viru
ebv
ebv
igm
serum
antibodi
immunosimpl
isebvvca
igm
test
kit
diamedix
co
miami
lake
fl
usa
serum
pct
concentr
measur
brahm
pct
kryptor
analyz
thermo
fisher
waltham
usa
wbc
count
band
differenti
percentag
mxa
protein
elisa
high
sensit
creactiv
protein
enzym
immunoassay
biocheck
foster
citi
ca
usa
refer
test
complet
central
laboratori
blind
patient
treat
clinician
studi
personnel
perform
febridx
test
refer
test
algorithm
classifi
patient
bacteri
infect
follow
criteria
met
throat
cultur
posit
bacteria
commonli
caus
pharyng
group
c
refer
test
algorithm
illustr
figur
patient
underw
follow
diagnost
test
throat
swab
bacteri
cultur
multiplex
polymeras
chain
reaction
pcr
combin
nasopharyng
oropharyng
npop
sampl
use
filmarray
respiratori
panel
biomerieux
inc
marcyletoil
franc
realtim
revers
transcriptas
pcr
npop
sampl
epsteinbarr
viru
ebv
ebv
igm
serum
antibodi
immunosimpl
isebvvca
igm
test
kit
diamedix
co
miami
lake
fl
usa
serum
pct
concentr
measur
brahm
pct
kryptor
analyz
thermo
fisher
waltham
usa
wbc
count
band
differenti
percentag
mxa
protein
elisa
high
sensit
creactiv
protein
enzym
immunoassay
biocheck
foster
citi
ca
usa
refer
test
complet
central
laboratori
blind
patient
treat
clinician
studi
personnel
perform
febridx
test
refer
test
algorithm
classifi
patient
bacteri
infect
follow
criteria
met
throat
cultur
posit
bacteria
commonli
caus
pharyng
group
c
streptococci
n
gonorrhoea
c
diphtheria
haemolyticum
plu
pct
ngml
throat
cultur
posit
bacteria
plu
pct
ngml
npop
sampl
pcr
posit
atyp
bacteria
pneumonia
c
pneumonia
b
pertussi
plu
pct
ngml
pct
ngml
plu
identifi
pathogen
pct
ngml
plu
wbc
cellsmcl
presenc
wbc
band
plu
identifi
pathogen
meanwhil
refer
test
algorithm
classifi
patient
viral
infect
follow
criteria
met
npop
sampl
pcr
posit
influenza
b
adenoviru
respiratori
syncyti
viru
rsv
human
metapneumoviru
parainfluenza
virus
npop
sampl
pcr
posit
ebv
plu
serum
igm
posit
ebv
pct
ngml
ngml
plu
wbc
cellsmcl
plu
wbc
band
plu
identifi
pathogen
patient
met
criteria
viral
bacteri
infect
patient
classifi
bacteri
patient
meet
criteria
bacteri
viral
infect
classifi
neg
refer
test
algorithm
studi
examin
outpati
uri
refer
method
develop
help
account
microbi
colon
refer
valu
pct
adult
children
older
h
ngml
less
major
pct
data
literatur
relat
bacterem
patient
sepsi
lower
respiratori
tract
infect
stolz
et
al
examin
pct
cutoff
varieti
respiratori
infect
demonstr
pct
ngml
sensit
bacteri
infect
specif
ngml
cutoff
sensit
bacteri
infect
decreas
specif
increas
specif
look
uri
condit
pharyng
elsammak
christiansen
et
al
show
pct
level
rang
ngml
ngml
median
valu
found
ngml
ngml
context
neg
filmarray
respiratori
panel
test
common
viral
atyp
bacteri
pathogen
associ
elev
wbc
presenc
band
elev
pct
level
ngml
like
bacteri
infect
measur
across
entir
patient
popul
two
physician
expertis
respiratori
infect
review
case
detail
review
use
refer
test
algorithm
classif
bacteri
viral
neg
guidelin
also
includ
review
clinic
laboratori
inform
avail
studi
case
report
form
includ
result
throat
cultur
molecular
respiratori
pathogen
panel
follow
blood
test
cbc
includ
wbc
diff
band
lymphocyt
procalcitonin
epsteinbarr
viru
igmigm
well
addit
standard
care
test
perform
includ
rapid
flu
rapid
strep
test
physician
review
case
togeth
came
consensu
classif
bacteri
viral
neg
physician
overread
could
lead
reclassif
compar
initi
classif
algorithm
thu
final
refer
standard
classif
bacteri
viral
neg
consist
algorithmguid
consensu
decis
physician
blind
febridx
result
initi
febridx
refer
standard
result
analyz
use
threecategori
classif
scheme
bacteri
vs
viral
vs
neg
agreement
febridx
refer
standard
calcul
use
unweight
cohen
kappa
statist
next
separ
evalu
febridx
accuraci
bacteri
viral
detect
bacteri
analysi
febridx
refer
standard
result
classifi
bacteri
vs
bacteri
dichotom
categori
analysi
viral
neg
result
collaps
bacteri
group
viral
analysi
result
reclassifi
viral
vs
viral
bacteri
neg
result
collaps
viral
group
sensit
specif
posit
neg
predict
valu
separ
calcul
bacteri
viral
detect
calcul
also
repeat
stratifi
studi
popul
age
group
year
year
year
confid
interv
sensit
specif
predict
valu
calcul
use
binomi
exact
method
confid
interv
kappa
statist
calcul
bootstrap
replic
statist
analys
conduct
stata
statacorp
colleg
station
tx
usa
addit
uri
popul
also
enrol
conveni
sampl
asymptomat
control
particip
test
febridx
specif
peopl
without
sign
symptom
infect
major
elig
criteria
asymptomat
control
popul
includ
age
year
fever
cough
chill
rhinorrhea
sore
throat
within
past
day
full
elig
criteria
display
supplement
tabl
febridx
measur
complet
asymptomat
control
describ
uri
popul
asymptomat
control
particip
undergo
refer
test
assum
neg
etiolog
refer
standard
patient
test
mxa
protein
elisa
high
sensit
creactiv
protein
enzym
immunoassay
asymptomat
control
popul
analyz
separ
primari
uri
studi
popul
specif
true
neg
rate
fals
posit
rate
febridx
calcul
studi
period
enrol
febril
uri
patient
enrol
uri
patient
underw
febridx
test
valid
febridx
result
one
patient
adequ
test
refer
standard
exclud
result
final
popul
uri
patient
analysi
popul
includ
children
year
old
adult
tabl
applic
refer
standard
includ
refer
test
algorithm
follow
physician
panel
overread
result
classifi
patient
bacteri
viral
neg
tabl
physician
panel
agre
classif
assign
algorithm
patient
two
patient
reclassifi
physician
panel
like
bacteri
infect
first
patient
throat
cultur
posit
heavi
growth
group
beta
hemolyt
streptococcu
gabh
pct
valu
ngml
thought
like
repres
bacteri
infect
presenc
gabh
cultur
neg
viral
pcr
panel
deem
like
bacteri
infect
second
case
demonstr
neg
microbiolog
test
elev
pct
ngml
elev
wbc
count
thousand
cellsmcl
tabl
among
bacteri
case
microbiolog
confirm
classifi
bacteri
base
biomark
measur
tabl
among
viral
case
microbiolog
confirm
patient
microbiologicallyconfirm
viral
infect
pct
ngml
pct
ngml
ngml
pct
ngml
overal
common
pathogen
influenza
n
parainfluenza
n
gabh
n
febridx
classifi
patient
bacteri
viral
neg
tabl
figur
use
threecategori
classif
scheme
overal
agreement
febridx
refer
standard
algorithm
kappa
ci
classifi
result
bacteri
vs
bacteri
overal
agreement
febridx
sensit
ci
specif
posit
predict
valu
ppv
neg
predict
valu
npv
diagnost
accuraci
bacteria
similar
across
age
group
tabl
among
patient
posit
throat
cultur
gabh
bacteri
result
febridx
bacteria
similar
across
age
group
tabl
among
patient
posit
throat
cultur
gabh
bacteri
result
febridx
five
patient
fals
neg
febridx
result
bacteri
detect
one
patient
throat
cultur
posit
gabh
pct
ngml
second
patient
npop
pcr
posit
chlamydophila
pneumonia
pct
ngml
remain
patient
neg
bacteri
cultur
pcr
test
classifi
bacteri
refer
algorithm
due
pct
concentr
ngml
ngml
concurr
white
blood
cell
count
thousand
cellsmcl
patient
presenc
band
patient
classifi
result
viral
vs
viral
febridx
refer
standard
overal
agreement
febridx
sensit
ci
specif
ppv
npv
trend
note
toward
higher
sensit
lower
specif
children
compar
adult
tabl
five
patient
fals
neg
febridx
result
bacteri
detect
one
patient
throat
cultur
posit
gabh
pct
ngml
second
patient
npop
pcr
posit
chlamydophila
pneumonia
pct
ngml
remain
patient
neg
bacteri
cultur
pcr
test
classifi
bacteri
refer
algorithm
due
pct
concentr
ngml
ngml
concurr
white
blood
cell
count
thousand
cellsmcl
patient
presenc
band
patient
classifi
result
viral
vs
viral
febridx
refer
standard
overal
agreement
febridx
sensit
ci
specif
ppv
npv
trend
note
toward
higher
sensit
lower
specif
children
compar
adult
tabl
small
subset
patient
document
versu
report
fever
rate
microbiolog
unconfirm
case
test
demonstr
bacteri
sensit
specif
viral
sensit
viral
specif
popul
studi
personnel
enrol
peopl
asymptomat
control
subject
two
subject
exclud
due
invalid
febridx
result
leav
subject
analysi
effort
made
enrol
repres
popul
howev
limit
number
pediatr
patient
year
includ
arm
studi
demograph
asymptomat
control
subject
similar
uri
popul
tabl
febridx
result
neg
asymptomat
control
subject
specif
ci
febridx
result
fals
posit
test
fals
posit
rate
ci
fals
posit
viral
result
fals
posit
bacteri
result
fals
posit
febridx
viral
result
confirm
mxa
elisa
test
ngml
febridx
fals
posit
bacteri
result
also
shown
accur
measur
elev
crp
mgl
confirm
crp
elisa
test
one
addit
patient
elev
crp
febridx
neg
mxa
elisa
crp
elisa
test
within
normal
rang
manuscript
describ
multicent
evalu
febridx
new
pointofcar
diagnost
test
design
rapidli
provid
clinician
action
bedsid
data
like
etiolog
uri
use
small
sampl
capillari
whole
blood
febridx
provid
measur
crp
mxa
biomark
associ
bacteri
viral
infect
respect
prospect
multicent
studi
outpati
febril
uri
asymptomat
control
febridx
sensit
specif
detect
bacteria
host
immun
respons
pathogen
virus
overal
sensit
specif
rang
limit
number
patient
less
year
old
enrol
bacteri
infect
make
challeng
compar
sensit
specif
valu
age
group
howev
viral
infect
equal
distribut
among
age
group
compar
sensit
febridx
test
found
higher
children
lower
specif
compar
age
group
suggest
children
unknown
factor
lead
elev
mxa
crossreact
antimxa
antibodi
like
partial
relat
activ
exclus
rhinoviru
coronaviru
shown
base
limit
filmarray
respiratori
panel
detect
viral
pathogen
parechovirus
human
bocaviru
specif
produc
us
epidem
date
trial
clinic
util
promis
technolog
defin
addit
studi
febridx
may
serv
import
tool
futur
effort
antibiot
stewardship
histor
hamper
lack
rapid
accur
diagnost
test
help
clinician
distinguish
viral
bacteri
infect
particular
strength
studi
includ
prospect
multicent
design
standard
procedur
definit
use
across
site
appropri
blind
febridx
refer
standard
result
personnel
made
febridx
refer
test
measur
inclus
asymptomat
control
popul
confirm
high
specif
febridx
asymptomat
popul
furthermor
current
studi
febridx
correctli
identifi
patient
gabh
pharyng
bacteri
inclus
gcbh
well
patient
acut
influenza
viral
accuraci
compar
favor
rapid
antigen
detect
test
gabh
influenza
clinician
routin
use
assist
decis
prescrib
antibiot
antivir
agent
febridx
provid
qualit
measur
high
vs
high
crp
mxa
crp
acut
phase
protein
link
presenc
sever
bacteri
infect
numer
studi
past
decad
crp
concentr
mgl
trigger
posit
crp
read
febridx
devic
previou
studi
suggest
patient
infecti
respiratori
symptom
crp
mgl
threshold
like
nonbacteri
selflimit
infect
crp
level
threshold
identifi
clinic
signific
immun
respons
reliabl
differenti
viral
bacteri
etiolog
therefor
febridx
also
includ
mxa
marker
viral
infect
mxa
deriv
type
interferon
like
interferon
upregul
presenc
viral
infect
mxa
broad
antivir
activ
rna
dna
virus
long
serum
halflif
mxa
elev
level
detect
day
viral
infect
provid
distinct
advantag
use
biomark
compar
interferon
variabl
transient
elev
respons
viral
infect
mxa
concentr
ngml
trigger
posit
read
febridx
level
identifi
sensit
threshold
identifi
viral
infect
combin
crp
mxa
singl
test
febridx
includ
sensit
marker
bacteri
viral
infect
current
studi
sought
evalu
accuraci
febridx
identifi
clinicallysignific
acut
bacteri
viral
uri
therefor
develop
refer
standard
algorithm
incorpor
multipl
individu
test
aim
identifi
bacteri
infect
host
respons
pathogen
viral
infect
figur
recogn
clinicallyimport
bacteri
uri
unlik
detect
throat
cultur
npop
pcr
classifi
cultureand
pcrneg
patient
bacteri
elev
pct
wbc
level
suggest
bacteri
infect
given
strong
associ
npop
pcr
detect
influenza
adenoviru
parainfluenza
rsv
human
metapneumoviru
symptomat
diseas
identif
virus
consid
pathogen
infect
algorithm
detect
virus
like
repres
asymptomat
detect
colonizationcarriag
rhinoviru
coronaviru
consid
pathogen
algorithm
final
refer
standard
etiolog
bacteri
vs
viral
vs
neg
also
includ
physician
overread
algorithm
result
allow
clinicallylog
classif
physician
overread
led
reclassif
case
similar
work
respiratori
infect
studi
lack
definit
refer
standard
classifi
viral
bacteri
etiolog
fact
lack
definit
etiolog
test
respiratori
infect
recogn
major
unmet
need
medicin
central
challeng
evalu
new
diagnost
test
field
acknowledg
algorithmbas
refer
standard
identifi
clinicallysignific
viral
bacteri
uri
imperfect
addit
test
could
incorpor
exampl
algorithm
includ
test
bocaviru
human
immunodefici
viru
hiv
howev
believ
transpar
standard
literaturebas
approach
use
provid
structur
reproduc
result
field
devoid
superior
altern
well
known
viral
infect
may
alter
oropharyng
nasopharyng
host
equilibrium
lead
bacteri
growth
enhanc
colon
necessarili
lead
clinic
signific
infect
pathogen
specif
isol
antigen
cultur
molecular
test
discrimin
colon
carrier
state
differenti
infect
colon
clinic
insignific
local
infect
requir
demonstr
system
antibodi
respons
although
immun
respons
clinic
impract
timedelay
may
lead
falseneg
result
follow
appropri
antibiot
therapi
studi
shown
children
gabh
isol
upper
respiratori
tract
present
symptom
tonsil
pharyng
demonstr
immun
respons
ivaska
et
al
show
patient
present
pharyng
gabh
alon
found
gabh
togeth
viru
group
c
g
bhemolyt
streptococci
gcbh
ggbh
alon
two
gcbh
ggbh
togeth
viru
three
one
virus
alon
case
patient
show
antistreptolysino
antibodi
increas
pair
serum
sampl
patient
antibodi
respons
three
gabh
posit
one
gcbh
posit
one
neg
streptococci
throat
cultur
blood
mxa
level
found
elev
patient
viral
pharyng
remain
low
patient
gabh
without
viru
detect
current
studi
viral
bacteri
pathogen
microbiolog
confirm
describ
singl
subject
subject
character
true
bacteri
infect
coinfect
rule
mxa
crp
elev
condit
seen
current
clinic
trial
defin
true
coinfect
requir
presenc
confirm
viru
pcr
presenc
bacteri
cell
cultur
growth
pcr
posit
atyp
bacteri
pathogen
associ
pct
elev
greater
ngml
andor
elev
wbc
use
definit
coinfect
confirm
low
associ
bacteri
coinfect
patient
uri
consist
low
coinfect
rate
found
et
al
studi
young
adult
anoth
studi
patient
suggest
higher
coinfect
rate
base
detect
rise
crp
level
subsequ
offic
visit
howev
like
overestim
sinc
crp
measur
made
independ
microbiolog
confirm
well
known
viral
infect
influenza
parainfluenza
epsteinbarr
herp
zoster
herp
simplex
adenoviru
may
lead
substanti
increas
crp
often
approach
mgml
even
though
febridx
differenti
rare
coinfect
npv
suggest
febridx
test
may
support
watch
wait
antibiot
strategi
wherein
patient
clinic
worsen
subsequ
h
initi
test
addit
reflex
microbiolog
test
empir
antibiot
therapi
could
consid
diagnost
test
interpret
context
clinic
pictur
independ
trauma
malnutrit
immunocompromis
patient
patient
underli
chronic
diseas
may
exhibit
alter
immun
respons
studi
febridx
reveal
ppv
bacteri
infect
larg
relat
lower
preval
bacteri
infect
compar
viral
infect
significantli
higher
ppv
report
pct
studi
evalu
ari
primari
care
patient
suggest
approxim
febridx
bacteri
posit
patient
repres
total
ari
patient
base
preval
could
receiv
unnecessari
antibiot
less
current
prescript
rate
larg
driven
treat
viral
infect
none
febridx
bacteri
fals
posit
occur
patient
microbiolog
confirm
viral
infect
studi
patient
microbiolog
confirm
viral
infect
elev
crp
mgl
elev
pct
ngml
could
contribut
overtreat
uri
requir
antibiot
treatment
often
receiv
unnecessari
antibiot
treatment
base
parent
patient
pressur
physician
fear
miss
seriou
bacteri
infect
davidson
et
al
show
febridx
alter
clinic
manag
decis
patient
ari
reduc
unnecessari
antibiot
prescript
strength
febridx
test
rest
high
npv
reduc
likelihood
miss
clinic
signific
bacteri
infect
defin
clinic
signific
bacteri
infect
requir
treatment
import
help
drive
antibiot
stewardship
oropharyng
nasopharyng
colon
occur
microorgan
detect
without
signific
associ
system
host
respons
may
affect
mani
host
factor
includ
immunosuppress
microbi
competit
use
antimicrobi
molecular
test
microbi
antigen
detect
may
detect
colon
postinfecti
shed
respiratori
pathogen
unknown
clinic
signific
arguabl
one
import
bacteri
pathogen
uri
gabh
treatment
gabh
may
necessari
associ
host
respons
sinc
rare
case
rheumat
fever
occur
patient
without
system
antibodi
respons
gabh
cultur
oropharynx
associ
antibodi
respons
suggest
true
infect
crp
elev
time
patient
uri
neg
initi
crp
test
seldom
show
rise
antibodi
titer
ninetysix
percent
uninfect
children
crp
mgml
putto
et
al
found
examin
children
posit
bacteri
cultur
show
crp
elev
mgl
recent
studi
adult
patient
acut
cough
fever
radiograph
confirm
pneumonia
steurer
et
al
conclud
pneumonia
could
safe
exclud
patient
crp
valu
mgl
patient
without
dyspnea
daili
fever
valu
mgl
valkenburg
et
al
shown
antistreptococc
antibodi
titer
accur
throat
cultur
predict
therapeut
outcom
crp
pct
shown
elev
uri
europ
crp
mgl
recommend
nation
institut
health
care
excel
nice
pneumonia
guidelin
trigger
prescrib
antibiot
random
control
studi
use
crp
pct
guid
antibiot
decis
shown
reduc
antibiot
prescript
without
increas
morbid
uri
lower
respiratori
tract
infect
lri
inabl
differenti
local
infect
without
associ
system
host
respons
clinic
signific
infect
associ
host
respons
may
result
unnecessari
antibiot
prescript
patient
microbiolog
confirm
lack
system
immun
respons
like
microbi
colon
dna
shed
previou
infect
clinic
insignific
local
infect
patient
without
microbi
confirm
limit
immun
respons
may
repres
potenti
less
signific
clinic
case
muri
enrol
current
studi
requir
patient
document
fever
report
fever
f
within
past
day
new
onset
cough
sore
throat
within
past
day
sinc
confirm
fever
found
possibl
muri
patient
never
febril
experienc
reactiv
airway
diseas
present
prior
significantli
develop
clinic
signific
infect
rate
muri
small
confirm
febril
subset
versu
complet
trial
demonstr
bacteri
sensit
specif
viral
sensit
viral
specif
suggest
clinic
perform
may
enhanc
presenc
confirm
febril
episod
studi
limit
first
discuss
definit
refer
standard
distinguish
viral
bacteri
respiratori
infect
use
algorithmbas
approach
maxim
reproduc
valid
refer
standard
misclassif
possibl
second
sought
enrol
consecut
elig
patient
due
practic
constraint
ship
biolog
sampl
avail
research
staff
popul
best
describ
conveni
sampl
third
includ
blood
sputum
cultur
test
bacteri
pathogen
due
low
anticip
yield
test
outpati
uri
acknowledg
includ
broader
rang
cultur
test
may
result
bacteri
identif
fourth
captur
inform
patient
index
visit
includ
followup
inform
later
visit
may
provid
addit
data
use
classifi
uri
viral
bacteri
fifth
despit
extens
test
uri
patient
classifi
neg
etiolog
refer
standard
similar
prior
studi
demonstr
larg
proport
patient
acut
respiratori
infect
pathogen
identifi
currentlyavail
test
sixth
larger
dataset
need
determin
role
febridx
pediatr
popul
febridx
novel
pointofcar
test
design
identifi
system
host
immun
respons
viral
bacteri
infect
rapid
measur
mxa
crp
small
sampl
capillari
blood
studi
diagnost
accuraci
febridx
test
sensit
specif
identifi
clinicallyimport
viral
bacteri
infect
febril
outpati
uri
febridx
potenti
assist
clinician
rapidli
distinguish
viral
bacteri
uri
promot
antibiot
stewardship
supplementari
materi
follow
avail
onlin
http
supplement
tabl
elig
criteria
upper
respiratori
tract
studi
popul
supplement
tabl
elig
criteria
asymptomat
control
studi
popul
